0
“The stream of that                                                     river Okyanos, whence                             ...
Evolution of Medicine  Surgery                  Drugs                    Devices         Stem and                         ...
“Every human walking the planet is a stem cell   product… (of) our father’s sperm and our mother’s   egg…When someone says...
Ischemic Conditions                  Stroke                  Cardiac                  Crohn’s Fistulas                    ...
AHA Cardiac Cell-Therapy Teach-in Nov, 2010  “Also, importantly, they   saw an effect of coronary   flow, so that’s an ind...
What Don’t We Know                                            Optimal #                     Best Delivery                 ...
What We Do Know                                                    Consistent, Strong,                                    ...
Patients                                                    Improved Reduced                        Reduced               ...
The Need for a Provision of Healthcare Service                                                    Cell Society Feb., 2011 ...
PRECISE: Sustained Functional Benefit                       20.0                                                  Control ...
PRECISE: Sustained Functional Benefit                                                                          Safe and   ...
What Patients Expect                                                             Chief                                    ...
OKYANOS Heart Institute                  First in world to provide an (expected) EU-Approved cardiac                  cell...
OKYANOS Heart InstituteOKYANOS Heart Institute ©2012 All Rights Reserved                       14
Upcoming SlideShare
Loading in...5
×

Okyanos Heart Institute - Cardiac Cell Therapy

358

Published on

The Okyanos Heart Institute brings a new standard of care and a better quality of life to patients with “no-option” coronary artery disease (CAD), utilizing a European Union–approved cell processing device.

Published in: Health & Medicine, Technology
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
358
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
4
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Transcript of "Okyanos Heart Institute - Cardiac Cell Therapy"

  1. 1. “The stream of that river Okyanos, whence is risen the seed of all the immortals.” Homer, Iliad 14.244ffOKYANOS Heart Institute ©2012 All Rights Reserved
  2. 2. Evolution of Medicine Surgery Drugs Devices Stem and Regenerative CellsOKYANOS Heart Institute ©2012 All Rights Reserved 2
  3. 3. “Every human walking the planet is a stem cell product… (of) our father’s sperm and our mother’s egg…When someone says they don’t believe in stem cells they don’t understand their own development. We’re walking stem cell products.”OKYANOS Heart Institute ©2012 All Rights Reserved 3
  4. 4. Ischemic Conditions Stroke Cardiac Crohn’s Fistulas Radiation and Other Chronic Wounds PVD Diabetic WoundsOKYANOS Heart Institute ©2012 All Rights Reserved 4
  5. 5. AHA Cardiac Cell-Therapy Teach-in Nov, 2010 “Also, importantly, they saw an effect of coronary flow, so that’s an index for new vessel formation, so they knew that these cells at least induced some new vessel formation, and that resulted in improved function of the heart.”OKYANOS Heart Institute ©2012 All Rights Reserved 5
  6. 6. What Don’t We Know Optimal # Best Delivery of Cells Method Optimal Best Cell Type # of TreatmentsOKYANOS Heart Institute ©2012 All Rights Reserved 6
  7. 7. What We Do Know Consistent, Strong, Improving Signals Cardiac Cell of Efficacy from Therapy is Not (Yet) Clinical Trials which a “Cure” Treated over 1000 Patients with Mesenchymal CellsOKYANOS Heart Institute ©2012 All Rights Reserved 7
  8. 8. Patients Improved Reduced Reduced Mortality Quality MACCE and of Life HospitalizationOKYANOS Heart Institute ©2012 All Rights Reserved 8
  9. 9. The Need for a Provision of Healthcare Service Cell Society Feb., 2011 Cytori Expects EU-Approval for No-Option CMIOKYANOS Heart Institute ©2012 All Rights Reserved 9
  10. 10. PRECISE: Sustained Functional Benefit 20.0 Control Cell 19.0 19 p < 0.05 p < 0.05 18.0 MVO2 (%) 17.2 17.1 17.0 16.6 16.0 15.0 15.5 15.3 Transplant 14.0 Baseline 6 Months 18 MonthsOKYANOS Heart Institute ©2012 All Rights Reserved 10
  11. 11. PRECISE: Sustained Functional Benefit Safe and Lower Infarct Feasible Cardiac MVO2 METS Size Through Mortality 18 Months RateSignificant Change Significant Change 8.2% Change At Avg. Follow Up at 18 Months at 18 Months at 6 Months of 28 Months: Correlates to Significant Change 2/6 Placebo PtsImproved Survival Died of Cardiac Causes ≤ 14 = 47% 1/21 Treated Pts1 Yr Survival Rate Died of Cardiac CausesOKYANOS Heart Institute ©2012 All Rights Reserved 11
  12. 12. What Patients Expect Chief Medical Officer Cell Next-Gen Processing Catheter Device U.S. State of the Art Center of Surgical Center Cath Lab Excellence Standards EU- Approved Patient Therapy Registry (Expected) Hospitality Trained- Staff Celution One is not approved in U.S.OKYANOS Heart Institute ©2012 All Rights Reserved 12
  13. 13. OKYANOS Heart Institute First in world to provide an (expected) EU-Approved cardiac cell therapy to patients with no-option ischemic heart disease Autologous Adipose-Derived Stem and Regenerative Cells via intramyocardial injection Center of Excellence built to OKYANOS specifications and U.S. surgical center standards in Freeport, Bahamas Expected opening Summer, 2012OKYANOS Heart Institute ©2012 All Rights Reserved 13
  14. 14. OKYANOS Heart InstituteOKYANOS Heart Institute ©2012 All Rights Reserved 14
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×